No Data
Is Hunan Jiudian Pharmaceutical (SZSE:300705) Using Too Much Debt?
Hunan Jiudian Pharmaceutical (300705.SZ): The company has ideas for external acquisition.
Gelonghui, December 17 - Hunan Jiudian Pharmaceutical (300705.SZ) recently stated during an investor relations event that the company has plans for external mergers and acquisitions and is currently looking for symbols that match its Global Strategy.
Hunan Jiudian Pharmaceutical (300705.SZ): The sales of Loxoprofen sodium gel patches are currently less affected by external pricing policies.
Gelonghui reported on December 17 that Hunan Jiudian Pharmaceutical (300705.SZ) recently stated in an investor relations activity that the sales of its Loxoprofen Sodium Gel Patch are currently less affected by the external pricing policy, with prices being largely consistent between hospitals and outside the hospital (both online and offline).
Hunan Jiudian Pharmaceutical (300705.SZ): It is expected that the flurbiprofen gel patch and indomethacin gel patch, which will be launched next year, will further enrich the product line of external topical patches.
On December 17, Galunhui reported that Hunan Jiudian Pharmaceutical (300705.SZ) recently indicated during investor relations activities that the sales channel for anti-inflammatory and pain-relieving plaster mainly relies on the OTC channel. Looking ahead, it is expected that the soon-to-be-launched flurbiprofen gel plaster and indomethacin gel plaster next year will further enrich the product line of topical plaster preparations, and with the existing sales resources and sales network, it can quickly penetrate into hospitals and chain markets. In addition, several generic drugs are expected to participate in the first round of national procurement, providing support for the company's future profit growth.
Shareholder Duan Lixin has reduced his shareholding in Hunan Jiudian Pharmaceutical (300705.SZ) by more than 1%.
Hunan Jiudian Pharmaceutical (300705.SZ) announced that the company recently received a "Share Reduction" document issued by shareholder Ms. Duan Lixin...
Insiders With Their Considerable Ownership Were the Key Benefactors as Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) Touches CN¥13b Market Cap
Risks To Shareholder Returns Are Elevated At These Prices For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705)
No Data
